Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Hammerson is ready for a Rerating
Shoppers are out in Force showing there presence
Brokers Rerating in January on the. Cards
Enjoy all
Just keep buying
The airport is packed and busy the flights are full
Not even possible to upgrade
These will double and triple Soon
Face masks are the normal here and around the world
The shops are packed
Hugely undervalued in my eyes
Travel stocks ready to takeoff
Face masks are here to stay together with the pcr Test
Holiday bookings are going thru the roof
Shopping centres are packed
Use the pull back to buy those travel stocks you will double if not triple your money by next year in my view
Happy Holidays
Travel stocks ready to take off
Travel stocks ready to takeoff
Face masks are here to stay together with the pcr Test
Holiday bookings are going thru the roof
Shopping centres are packed
Use the pull back to buy those travel stocks you will double if not triple your money by next year in my view
Happy Holidays
Travel stocks ready to takeoff
Face masks are here to stay together with the pcr Test
Holiday bookings are going thru the roof
Shopping centres are packed
Use the pull back to buy those travel stocks you will double if not triple your money by next year in my view
Happy Holidays
Business as usual with face mask s
Higher highs will be here soon enough
Business as usual with face masks
Higher highs will be here again
Holiday season is open with Face masks
This will see Higher highs again very soon
Shopping Centres are Packed
Cat is out of the bag
Carlisle were after a bargain
This is worth ten times more then where we are now
TakeOver still on the cards
Just keep buying
You will be rewarded
IAG ready to climb to 220pence
Make no mistake we are ready and will be climbing to 220 pence so just Buckle Up Enjoy the flight up
Buy The Shares Now
Buy the Rights Later
You will use the profits to go free on Holiday
With Tui
Enjoy
This is going to fly High
Everyone has Holiday on there mind Nothing Else
In my view
The trading situation is very strong for Tui
These will Double by next year
Fill your boots
I stick to my prediction
ReRating is imminent 130pence will be swift With 150pence Very Soon
200pence by the end of 2021 is Viable
Make no mistake of the numbers
Or there Targets
2021 is the volcano year for Vectura
Royalty income, litigation win see Vectura beat expectations
Thu, 18th Mar 2021 07:43
(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.
The FTSE 250 inhaled pharmaceuticals company said product supply revenue decreased 4.4% year-on-year in 2020 to £109.9m, although product supply revenues from 'flutiform' were marginally ahead of guidance at £95.8m.
Development services revenues, meanwhile, advanced 4.4% to £11.9m, which the board put down to a contribution from new contract development and manufacturing organisation (CDMO) agreements in the second half.
Royalty and other marketed revenues rocketed 32.6% to £68.8m, driven by milestones and fourth quarter GlaxoSmithKline 'Ellipta' royalties of £6.5m, following a successful outcome from litigation in the United States.
Gross profit increased 6.4% to £101.4m, and adjusted EBITDA was 41.7% firmer at £61.5m, which was also put down to the increase in royalty and other marketed revenues, and a material decrease in research and development investment.
Operating profit came in at £132.8m, swinging from a loss of £27m in 2019, which was driven by the recognition of £121.1m of exceptional income for damages and interest associated with the enforcement of a patent covering three US GlaxoSmithKline 'Ellipta' products, and improved adjusted EBITDA performance.
Vectura said it maintained strong liquidity, with closing cash and cash equivalents rising to £78.6m from £74.1m a year earlier, reflecting free cash flow generation of £24.1m and a share buyback of about £16.4m during the year.
On the operational front, Vectura described a "strong" execution of its strategy, with a new business development team now established with a presence on the east and west coasts of the US, as well as Europe and the UK.
A total of 18 new CDMO contracts were signed during 202, contributing £3m to second half revenues.
Vectura also made progress across its co-development pipeline, with approval of 'VR315', its generic 'Advair' programme in partnership with Hikma, coming in December and triggering milestone payments of $11m.
The approval of 'Enerzair Breezhaler' in Japan and Europe, meanwhile, triggered milestones of $6.25m.
Vectura said its "operational transformation" was ongoing, with a phased transition of research and development operations from Switzerland to the UK now underway.
Since the year ended, and following a review of the firm's capital allocation priorities, the board said it had approved in principle a special dividend of around £115m, to be paid during 2021.
"The business has performed well during 2020, delivering financial performance ahead of expectations," said chief executive officer Will Downie.
"We are pleased with the progress we have made against our inhalation CDMO strategy, signing 18 deals during 2020, with £3.0m revenue recognised in the sec
Facts speak for themselves
Vectura is hugely undervalued at this level s
150pence is the realistic price knowing all the facts are out today
Rikkkki that’s your view
But have you looked at yourself lately
Before calling people Names
So childish
Strong Results
Special Dividend
Better then Expected Trading
Leaves Around £200million Cash in the bank
130pence in Open with 150pence Soon after
Enjoy the Ride up